Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice.

James Mu,Guoquiang Jiang,Edward J. Brady,Qing Dallas-Yang,Franklin Liu,John Woods,Emanuel Zycband,Michael Wright,Zhihua Li,Lu K,Lan Zhu,Xiaolan Shen,Sinharoy R,Candelore Ml,Sajjad A. Qureshi,Dong-Ming Shen,Fengqi Zhang,Emma R. Parmee,Bin Zhang

Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice.

2011

James Mu
Guoquiang Jiang
Edward J. Brady
Qing Dallas-Yang
Franklin Liu
John Woods
Emanuel Zycband
Michael Wright
Zhihua Li
Lu K
Lan Zhu
Xiaolan Shen
Sinharoy R
Candelore Ml
Sajjad A. Qureshi
Dong-Ming Shen
Fengqi Zhang
Emma R. Parmee
Bin Zhang

Aims/hypothesis Antagonism of the glucagon receptor (GCGR) represents a potential approach for treating diabetes. Cpd-A, a potent and selective GCGR antagonist (GRA) was studied in preclinical models to assess its effects on alpha cells.

Keywords:

Glucagon
Antagonism
Glucagon-like peptide 1 receptor
Glucagon receptor
Glucagon-like peptide-1
Alpha cell
Type 2 diabetes
Diet-induced obese
Endocrinology
Internal medicine
Biology
Alpha (ethology)
Antagonist

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations